#United States #Princeton #Miguel Forte #P. Wotton #Shishir Gadam

Made Scientific Creates Scientific Advisory Board with Key Industry Leaders

Made Scientific has recently announced the establishment of its Scientific Advisory Board (SAB), aimed at propelling the company's advancements in the field of cell therapy. With the appointment of notable experts including Miguel Forte, M.D., Ph.D., Paul K. Wotton, Ph.D., Shishir Gadam, Ph.D., and Young K. Hong, M.D., the SAB is poised to significantly impact the trajectory of Made Scientific's mission.

The Vision Behind the SAB

The SAB's core objective is to foster innovation within Made Scientific's operational framework. The members bring a wealth of experience from diverse segments of the cell therapy landscape, including product translation, bioprocessing, analytical technologies, regulatory affairs, and clinical applications. This multidisciplinary approach will assist in refining Made Scientific's CDMO platform — making it more efficient, automated, and cost-effective.

Syed T. Husain, the Chairman and CEO of Made Scientific, emphasized the importance of this foundational board, stating, "This marks a pivotal moment in our commitment to innovation. Each member offers world-class expertise across cell therapy, manufacturing science, and clinical practice, directly influencing our service priorities."

Profiles of the Board Members

• - Miguel Forte, M.D., Ph.D.: Currently the CEO of Kiji Therapeutics, Dr. Forte is recognized as an influential figure in the field. His prior experience includes leadership roles at Bone Therapeutics and the European Medicines Agency (EMA). Dr. Forte’s extensive background in regenerative medicine makes him a crucial asset to the board.

• - Paul K. Wotton, Ph.D.: Serving as the CEO and Chairman of RBL LLC, Dr. Wotton has considerable experience in the biotech sector, holding multiple executive leadership roles in companies focused on innovative therapies. His expertise is expected to amplify Made Scientific's strategic initiatives.

• - Shishir Gadam, Ph.D.: With a solid technical background, Dr. Gadam is the Chief Technical Officer at Marea Therapeutics. His previous roles at Juno Therapeutics involved launching commercial CAR-T therapies, equipping him with vital insights into the complexities of cell therapy production.

• - Young K. Hong, M.D.: A dual board-certified surgeon, Dr. Hong is heavily involved in clinical research related to cellular therapies. His clinical experience and research background in immunotherapy and surgical oncology will guide the SAB in aligning clinical needs with manufacturing capabilities.

Strategic Objectives and Future Plans

The formation of the SAB is a strategic move towards enhancing Made Scientific's capacity to lower the cost of goods (COGS) associated with cell therapy manufacturing. By focusing on more streamlined processes, the company aims to facilitate its partners in providing more accessible and reliable therapies to patients around the globe.

Made Scientific intends to broaden the board’s composition later this year, indicating a commitment to continuous improvement and an ambitious blueprint for future developments in cell therapy.

Conclusion

With cutting-edge manufacturing facilities and now a powerhouse of advisory expertise, Made Scientific is well-positioned to carve out new pathways in the realm of cell therapy, aligning its innovations with the evolving demands of the healthcare landscape. Their mission, encapsulated as "Defy Limits. Deliver Results," encapsulates their determination to make a significant impact in the field.

For further updates and information, please visit madescientific.com or contact them at [email protected]